...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive Diseases and Sciences >Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population.
【24h】

Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population.

机译：单中心炎症性肠病人群中淋巴瘤的发病率和危险因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS: Previous studies on the risk of lymphoma in inflammatory bowel disease (IBD) have yielded conflicting results. We aim to determine the incidence and risk factors for lymphoma in a large IBD population. METHODS: Patients with lymphoma were identified from a single-center IBD database. The standardized incidence ratio (SIR) of lymphoma was estimated using data from the Surveillance, Epidemiology and End Results (SEER) registry. Risk factors for lymphoma were determined by comparing cases with a matched IBD control group. RESULTS: Eleven lymphomas were identified among 3,585 IBD patients during an average of 8.4 years of observation. Three patients were excluded. In the remaining eight, median age at diagnosis was 47 years and mean IBD duration was 20 years (range 7.5-45 years). The SIR for lymphoma was 1.6 [95% confidence interval (CI) 0.6-3.0], and for non-Hodgkin lymphoma (NHL), 1.5 (0.3-2.8). Three lymphoma patients (38%) received prior immunomodulators and two (25%) received biologics, versus 57% and 39% in the control group, respectively (P = 0.4). No correlation was seen with tobacco exposure, disease duration, use, or dose or duration of immunosuppressive therapy. CONCLUSIONS: In this IBD cohort, risk of lymphoma was not increased compared with the general population. Risk of lymphoma was not associated with any demographic or therapy-related factors.
机译：目的：先前关于炎症性肠病（IBD）中淋巴瘤风险的研究得出了相互矛盾的结果。我们旨在确定大量IBD人群中淋巴瘤的发生率和危险因素。方法：从单中心IBD数据库中鉴定出淋巴瘤患者。淋巴瘤的标准化发生率（SIR）是使用监测，流行病学和最终结果（SEER）注册中心的数据估算的。通过将病例与匹配的IBD对照组进行比较，确定淋巴瘤的危险因素。结果：在平均8.4年的观察期间，在3585例IBD患者中鉴定出11例淋巴瘤。三名患者被排除在外。在其余的八个中，诊断时的中位年龄为47岁，平均IBD持续时间为20年（范围为7.5-45岁）。淋巴瘤的SIR为1.6 [95％置信区间（CI）0.6-3.0]，非霍奇金淋巴瘤（NHL）的SIR为1.5（0.3-2.8）。 3名淋巴瘤患者（38％）接受了事先的免疫调节剂，2名（25％）接受了生物制剂，而对照组分别为57％和39％（P = 0.4）。没有发现与烟草暴露，疾病持续时间，使用或免疫抑制治疗的剂量或持续时间相关。结论：在这个IBD队列中，与普通人群相比，淋巴瘤的风险没有增加。淋巴瘤的风险与任何人口统计学或治疗相关因素均无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号